<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03223987</url>
  </required_header>
  <id_info>
    <org_study_id>BS2016.1</org_study_id>
    <nct_id>NCT03223987</nct_id>
  </id_info>
  <brief_title>Influence of a Food Supplement on the Gut Microbiome in Healthy Obese Women</brief_title>
  <official_title>Influence of a Food Supplement on the Gut Microbiome in Healthy Obese Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bio-Strath AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Zentrum für Adipositas- und Stoffwechselmedizin Winterthur GmbH</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Bio-Strath AG</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Before and after study in obese women 25-35 years old, BMI 30-35, taking Strath® Kräuterhefe&#xD;
      Original (liquid), Herbal Yeast Food Supplement for three weeks. At the beginning and after&#xD;
      three weeks of the study a stool sample is provided. These samples are analysed with 16S rRNA&#xD;
      analysis down to species level.The results are interpreted with the PICRUSt classification&#xD;
      and Alpha Diversity Analysis and compared to internationally accepted data bases.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Intervention: Variation of the gut microbiome via intake of an herbal yeast preparation.&#xD;
&#xD;
      Participants: healthy obese women between 25 and 35 years. Intervention to be studied: Intake&#xD;
      of Strath® Kräuterhefe Original (liquid), Herbal Yeast Food Supplement over 3 weeks, stool&#xD;
      analysis.&#xD;
&#xD;
      Sequence and duration of all study periods: 7 weeks per proband.&#xD;
&#xD;
      Week -4 - -2: Pre-Phase Hand out study information First check of inclusion/exclusion&#xD;
      criteria&#xD;
&#xD;
      Week -2: Initiation-Phase Signed &quot;Informed Consent&quot; Second check of inclusion/exclusion&#xD;
      criteria Complete assessment Part I, II (see 8.2) Start assessment Part IV (see 8.2)&#xD;
&#xD;
      Week 0: Intervention-Phase Implementation of food supplement Complete assessment Part III&#xD;
      (see 8.2) Third check of inclusion/exclusion criteria&#xD;
&#xD;
      Week 3: Evaluation-Phase Complete assessment Part II, III and IV Fourth check of&#xD;
      inclusion/exclusion criteria Compliance control&#xD;
&#xD;
      5.2 Methods of minimising bias (ICH/E6 6.4.3; AGEK 4.3; SPIRIT #16, 17) ICH: A description of&#xD;
      the measures taken to minimize/avoid bias, including: Randomization, Blinding.&#xD;
&#xD;
      Homogenous sample selection. 5.2.1 Randomisation Not applicable&#xD;
&#xD;
      5.2.2 Blinding procedures Not applicable&#xD;
&#xD;
      5.2.3 Other methods of minimising bias The investigators are going to do a semi-quantitative&#xD;
      screening to determine a participant's nutritional habits.&#xD;
&#xD;
      Questions about their nutritional habits asked in the screening (via questionnaire);&#xD;
&#xD;
        1. Does the participant have a particular or alternative lifestyle (e.g. vegan, vegetarian,&#xD;
           only eating raw fruits and vegetables, etc.)?&#xD;
&#xD;
           - if yes → excluded&#xD;
&#xD;
        2. Does the participant control your nutrition in any form (food diary, app, counting&#xD;
           calories, etc.)?&#xD;
&#xD;
           - if yes → excluded&#xD;
&#xD;
        3. Does the participant consciously eat food to strengthen your immune system or do you&#xD;
           take additional supplements to influence your intestinal bacteria (e.g. pro- and/or&#xD;
           prebiotic food like Actimel, Activia, etc.)?&#xD;
&#xD;
           - if daily or weekly → excluded&#xD;
&#xD;
        4. Does the participant exercise regularly? If yes, how often? - if 3h/week or more →&#xD;
           excluded&#xD;
&#xD;
        5. On how many days per week does the participant eat meat or meat products?&#xD;
&#xD;
           - if less then twice and more than five times peer week → excluded&#xD;
&#xD;
        6. On how many days per week does the participant eat fish?&#xD;
&#xD;
           - if less or more than twice per week / 5 times per month → excluded&#xD;
&#xD;
        7. On how many days per week does the participant eat salad, vegetables or vegetable juice&#xD;
           (not counting potatoes)?&#xD;
&#xD;
           - if less than 5 days per week → excluded&#xD;
&#xD;
        8. On how many days per week does the participant eat fruits or drink fruit juices&#xD;
           approximately?&#xD;
&#xD;
           - if less than 5 days per week → excluded&#xD;
&#xD;
        9. On how many days per week does the participant drink or eat milk or milk products&#xD;
           approximately? - if less than 4 days per week → excluded&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">May 11, 2017</start_date>
  <completion_date type="Anticipated">August 15, 2019</completion_date>
  <primary_completion_date type="Anticipated">July 15, 2019</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Before-after intervention, open label study</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Care Provider)</masking>
    <masking_description>First letter of prename, second and third letter of name.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Quantitative difference in microbiome composition.</measure>
    <time_frame>Six weeks.</time_frame>
    <description>BoosterShot shotgun sequencing analysis down to the species level and compared with internationally accepted data banks. Comparison before-after.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>BMI</measure>
    <time_frame>Three weeks</time_frame>
    <description>Analysing the influence of the food additive on obesity parameters.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Overweight</condition>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Strath® Kräuterhefe Original (liquid)</intervention_name>
    <description>The food supplement is taken 3 x 1 coffee spoon à 5ml = 15ml per day for three weeks.&#xD;
Stool analysis at 2nd visit and last visit. Before-after study.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Women, 25 to 35 years, BMI 30-35&#xD;
&#xD;
          -  German speaking&#xD;
&#xD;
          -  Smartphone owner&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Contraindications to the class of drugs under study, e.g. known hypersensitivity or&#xD;
             allergy to class of drugs or the investigational product,&#xD;
&#xD;
          -  Women who are pregnant or breast feeding,&#xD;
&#xD;
          -  Intention to become pregnant during the course of the study,&#xD;
&#xD;
          -  Lack of safe contraception, defined as: Female participants of childbearing potential,&#xD;
             not using and not willing to continue using a medically reliable method of&#xD;
             contraception for the entire study duration, such as oral, injectable, or implantable&#xD;
             contraceptives, or intrauterine contraceptive devices, or who are not using any other&#xD;
             method considered sufficiently reliable by the investigator in individual cases.&#xD;
&#xD;
          -  Please note that female participants who are surgically sterilised / hysterectomised&#xD;
             or post-menopausal for longer than 2 years are not considered as being of child&#xD;
             bearing potential.&#xD;
&#xD;
          -  Other clinically significant concomitant disease states (e.g., renal failure, hepatic&#xD;
             dysfunction, cardiovascular disease, etc.),&#xD;
&#xD;
          -  Known or suspected non-compliance, drug or alcohol abuse,&#xD;
&#xD;
          -  Inability to follow the procedures of the study, e.g. due to language problems,&#xD;
             psychological disorders, dementia, etc. of the participant,&#xD;
&#xD;
          -  Participation in another study with investigational drug within the 30 days preceding&#xD;
             and during the present study,&#xD;
&#xD;
          -  Enrolment of the investigator, his/her family members, employees and other dependent&#xD;
             persons&#xD;
&#xD;
          -  any kind of nutritional intervention due to a disease in the past 6 months&#xD;
&#xD;
          -  any mean of weight reduction in the past 6 months&#xD;
&#xD;
          -  Severe health problems in the last 6 months&#xD;
&#xD;
          -  Chronic digestive system problems&#xD;
&#xD;
          -  Medication against constipation and diarrhea&#xD;
&#xD;
          -  Mental problems&#xD;
&#xD;
          -  Major surgery&#xD;
&#xD;
          -  Allergies or Atopy&#xD;
&#xD;
          -  Drug intolerance&#xD;
&#xD;
          -  Antibiotics within 12 months before study&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>xy genome</gender_description>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter W. Joller, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Dr.Joller BioMedical Consulting</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Peter W. Joller, PhD</last_name>
    <phone>+41443617353</phone>
    <email>medsciences@gmx.net</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Susanne Maurer, MD</last_name>
    <phone>+41522350502</phone>
    <email>dr.smaurer-wiesner@hin.ch</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Center for Obesity and Metabolism Adimed - Zentrum für Adipositas- und Stoffwechselmedizin Winterthur GmbH Lagerhausstrasse 9</name>
      <address>
        <city>Winterthur</city>
        <state>Kanton Zurich</state>
        <zip>8400</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susanne Maurer, MD</last_name>
      <phone>+41522350502</phone>
      <email>dr.smaurer-wiesner@hin.ch</email>
    </contact>
    <contact_backup>
      <last_name>Annette Fehr</last_name>
      <phone>+41522350502</phone>
      <email>Annette Fehr &lt;a.fehr@adimed.ch&gt;</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>July 11, 2017</study_first_submitted>
  <study_first_submitted_qc>July 19, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 21, 2017</study_first_posted>
  <last_update_submitted>May 20, 2019</last_update_submitted>
  <last_update_submitted_qc>May 20, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 21, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Bio-Strath AG</investigator_affiliation>
    <investigator_full_name>Peter Joller, PhD</investigator_full_name>
    <investigator_title>Peter Joller, PhD Clinical Immunology FAMH</investigator_title>
  </responsible_party>
  <keyword>16S rRNA</keyword>
  <keyword>Microbiome</keyword>
  <keyword>Strath Herbal Yeast Preparation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Overweight</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>After study termination we decide if for publication other researchers will be involved</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

